S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs by Hanifeh, Mohsen et al.
RESEARCH ARTICLE Open Access
S100A12 concentrations and
myeloperoxidase activity in the intestinal
mucosa of healthy dogs
Mohsen Hanifeh1,2*, Romy M. Heilmann3, Satu Sankari1, Minna M. Rajamäki1, Laura Mäkitalo4, Pernilla Syrjä5,
Susanne Kilpinen1, Jan S. Suchodolski3, Jörg M. Steiner3 and Thomas Spillmann1
Abstract
Background: Relatively few laboratory markers have been evaluated for the detection or monitoring of intestinal
inflammation in canine chronic enteropathies, including inflammatory bowel disease (IBD). Previous research found
that the intestinal mucosal levels of S100A12 and myeloperoxidase (MPO), as biomarkers of gut inflammation, were
elevated in human patients with IBD. To date, the S100A12 and MPO levels in intestinal mucosal samples from
either healthy dogs or from dogs suffering from IBD remain unreported. Therefore, this study aimed to evaluate the
mucosal S100A12 and MPO levels in four different parts of the intestine (duodenum, jejunum, ileum and colon) in
12 healthy laboratory Beagle dogs using the ELISA and spectrophotometric methods, respectively.
Results: Based on histological examinations, the recorded findings for all the samples were considered normal. The
mucosal concentration of S100A12 in the ileum was significantly higher than in all other segments of the intestine
(p < 0.05). MPO activity was significantly higher in the ileal, jejunal and duodenal than in colonic mucosal samples
(p < 0.05). Moreover, its concentration was higher in the jejunum than in the duodenum.
Conclusions: This study showed that S100A12 and MPO are reliably detectable in canine intestinal mucosa. The
assays used appeared to be sufficient to further evaluate the role of S100A12 and MPO in the pathogenesis of
canine chronic enteropathies, including IBD. These biomarkers may play a role in the initial detection of gut
inflammation suggesting the need for further investigations to confirm IBD or to differentiate between IBD
subtypes. Understanding the role of S100A12 and MPO in the pathogenesis of chronic intestinal inflammation in
future may result in an improved understanding of canine chronic intestinal inflammation.
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Background
In canine medicine, a limited number of laboratory
markers for the detection or monitoring of localised
(e.g., gastrointestinal) or systemic inflammation exists
[1]. The diagnosis of canine inflammatory bowel disease
(IBD), for example, often poses challenges for the veter-
inarian and relies on the exclusion of other diagnoses
and the histopathological evaluation of intestinal muco-
sal biopsies [2, 3]. In addition, neither clinical signs nor
clinicopathological markers allow the clinician to predict
whether a dog with chronic idiopathic IBD will respond
to a change in diet alone, to antibiotics or to corticoste-
roids [4]. Thus, objective biomarkers may help to sim-
plify diagnosis and possibly predict the most appropriate
treatment approach in canine IBD.
S100A12 (also known as calgranulin C) belongs to the
S100/calgranulin-protein family and represents a useful in-
flammatory marker in human patients with inflammatory
diseases, such as systemic lupus erythematosus [5],
rheumatoid arthritis [6], respiratory disease [7, 8] and IBD
[9–16]. S100A12 is mostly expressed and secreted by acti-
vated phagocytes [17] and, at lower levels, by keratinocytes
[18], monocytes [19] and eosinophils [19]. S100A12 plays a
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role in intracellular homeostasis and possesses extracellular
functions, including chemotaxis, proinflammatory cytokine
production, sustained recruitment of leukocytes and in-
duction of oxidative stress [19–21]. Increased S100A12
concentrations were found in the stool samples, serum and
intestinal mucosa in human patients with IBD [10–16]. Re-
cently, canine S100A12 was purified [22], and a radio-
immunoassay was developed and analytically validated for
its quantification in serum and faecal [23] and urine sam-
ples from dogs [24]. Furthermore, an S100A12 concentra-
tion was recently measured as a non-invasive marker in the
faeces of dogs with and without IBD using the ELISA
method [25]. That study showed that dogs with IBD have
higher faecal S100A12 concentrations than healthy dogs.
However, when measuring only the faecal S100A12
concentration, it is impossible to know from which part of
the intestine they originate. Given the various roles of
S100A12, it is reasonable to consider this protein’s function
in the intestinal mucosa during inflammation.
Myeloperoxidase (MPO) is an enzyme found mostly in
neutrophils as well as at lower concentrations in mono-
cytes and macrophages [26, 27]. It plays a major role in
intracellular microbial destruction, but, at inflammatory
sites, it is released into the extracellular space after phago-
cyte activation and induces damage to the host tissue [28].
Increased intestinal tissue levels of MPO as a biomarker
of oxidative stress were found in the animal models of
IBD [29–31] and in both forms of human IBD [Crohn’s
disease (CD) and ulcerative colitis (UC)] [32–34]. This
finding raises the question of whether mucosal MPO ac-
tivity may also be associated with canine IBD. In canine
IBD, the predominant inflammatory cells are thought to
be lymphocytes and plasma cells. However, German et al.
also found a significant increase in the number of neutro-
phils and macrophages in dogs with antibiotic-responsive
diarrhoea and in dogs with IBD when compared to
healthy controls [35]. To our knowledge, no reports of
S100A12 and MPO levels in intestinal mucosal samples
from healthy dogs or dogs with IBD exist.
To initiate research on this aspect of canine intestinal
inflammation, our study aimed to determine the muco-
sal S100A12 and MPO levels in different parts of the in-
testine in 12 healthy laboratory Beagle dogs. The results
of this study provide the basis for future studies re-
garding the role of mucosal S100A12 and MPO as in-
flammatory biomarkers in the pathogenesis of canine
chronic enteropathies, including IBD.
Results
Histological examination
Based on the histological examination of the intestine,
the median total WSAVA score of all samples was 0
(range 0–3), classifying all findings as normal. We found
no histological abnormalities in the submucosa, the
muscularis externa or the serosa in any of the samples.
S100A12 concentrations in the intestinal mucosa
The S100A12 concentration in all samples ranged from
2.5–237.6 μg/L. In the four different parts of the intes-
tine examined in 12 healthy dogs, the highest median
levels of S100A12, which were significant, were found in
the ileum (71.5 μg/L [38.9–141.9]), followed by the colon
(23.2 μg/L [6.7–75.6]), duodenum (11.4 μg/L [6.9–28.5])
and jejunum (8.5 μg/L [5.1–19.3]) (Table 1 and Fig. 1).
In addition, the difference between the colonic and je-
junal mucosa was significant (p < 0.05).
Analytical validation of the MPO method and MPO
activity in the intestinal mucosa
The intra-assay coefficients of variation (CV %) in six dif-
ferent small intestinal mucosa samples assayed in a 1:2 di-
lution were 0.77, 0.85, 1.80, 1.56, 0.64 and 1.02 %, and
were 1.55, 1.84, 1.24, 1.30, 1.03 and 1.03 % in six different
large intestinal mucosa samples tested in a 1:2 dilution.
The inter-assay CV % for six different small intestinal and
six different large intestinal mucosa samples assayed in a
1:2 dilution were 1.77, 0.37, 2.55, 2.24, 1.32 and 2.59 %,
and 7.00, 7.59, 1.76, 2.74, 1.00 and 1.66 %.
Table 1 Distribution of the S100A12 concentrations and MPO activities in the intestinal mucosal samples of 12 healthy dogs
Intestinal
segment
Dog No 1 2 3 4 5 6 7 8 9 10 11 12
Variable
Duodenum S100A12 (μg/L) 6.0 27.9 7.3 5.4 27.0 45.8 28.7 14.0 30.3 8.7 6.7 8.0
MPO (ΔA/min) 0.61 0.35 0.46 0.03 0.17 0.09 0.7 0.08 0.11 0.62 0.54 0.1
Jejunum S100A12 (μg/L) 7.3 22.1 2.5 5.0 31.3 20.8 9.6 5.5 11.9 5.8 2.7 14.8
MPO (ΔA/min) 5.12 1.04 2.15 0.22 0.26 0.32 1.92 0.37 0.22 0.35 0.85 0.36
Ileum S100A12 (μg/L) 38.1 143.0 41.2 18.3 91.6 209.6 138.4 90.8 237.6 52.1 44.1 20.0
MPO (ΔA/min) 0.18 1.14 1.25 0.16 0.8 1.33 1.43 0.18 0.22 0.72 0.55 0.28
Colon S100A12 (μg/L) 11.5 123.4 64.4 5.2 79.3 57.6 4.2 6.8 34.9 94.4 6.6 7.0
MPO (ΔA/min) 0.2 0.12 0.14 0.06 0.1 0.14 0.03 0.05 0.04 0.52 0.03 0.09
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The observed to expected ratios (O/E) at dilutions of
1:2, 1:4, 1:8 and 1:16 ranged from 91.6–106.9 % (mean ±
SD: 98.3 ± 3.8 %) for six different small intestinal mucosa
samples, and from 84–103.8 % (93.6 ± 4.9 %) for six dif-
ferent large intestinal mucosa samples. O/E for the spik-
ing recovery ranged from 97.3–111.1 % (103.7 ± 4.8 %)
for five different small intestinal mucosa samples, and
from 90.2–103.8 % (97.1 ± 4.4 %) for five different large
intestinal mucosa samples.
The MPO enzyme activity was determined in all mu-
cosal samples from four different intestinal areas of 12
healthy Beagles. The median MPO activity was signifi-
cantly higher in the ileum (0.49 ΔA/min [0.19–1.05]), je-
junum (0.36 ΔA/min [0.28–1.70]) and duodenum (0.26
ΔA/min [0.09–0.59]) than in the colon (0.09 ΔA/min
[0.04–0.14]) (p < 0.05) (Table 1 and Fig. 2). In addition,
the difference between the jejunal and duodenal mucosa
was significant (p < 0.05) (Fig. 2).
Fig. 1 Boxplot representing the log-transformed S100A12 concentrations in the intestinal mucosal samples of 12 healthy dogs. The horizontal line
inside each box represents the median; the top and bottom of each box represent the 75th and 25th percentiles, respectively; and the whiskers
represent the 95th and 5th percentiles. *p < 0.05 vs. duodenum, jejunum and colon; # p < 0.05 vs. jejunum
Fig. 2 Boxplot representing the log-transformed MPO activities in the intestinal mucosal samples of 12 healthy dogs. The horizontal line inside
each box represents the median; the top and bottom of each box represent the 75th and 25th percentiles, respectively; and the whiskers represent
the 95th and 5th percentiles. *p < 0.05 vs. colon; # p < 0.05 vs. duodenum
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Discussion
This study aimed to determine the concentration of
S100A12 and the activity of MPO in four different parts
of the intestine in healthy Beagles by using ELISA and a
spectrophotometric method, respectively. The ELISA
method was validated as capable of determining S100A12
in the faecal samples of healthy dogs [25] and dogs with
IBD [25], but to the best of our knowledge not in canine
intestinal mucosal extracts. In this study, we successfully
established and validated for the first time a spectrophoto-
metric method to measure MPO activity in the intestinal
mucosa in healthy dogs.
According to the literature, the interpretation of
gastrointestinal histopathological findings may vary
widely between pathologists even with standardised
grading schemes [36, 37]. Despite using a pictorial template,
Willard et al. found poor agreement between pathologists
evaluating the number of duodenal neutrophils in dogs and
cats when using a four-point scale (0 = normal, 1 =
mild, 2 = moderate, 3 = severe) [37]. Hence, applying
objective biomarkers may overcome this problem.
S100A12 and MPO are exclusively expressed in relevant
amounts by granulocytes, which play an important role in
the pathogenesis of IBD in humans [15, 34].
Elevated intestinal mucosal concentrations of S100A12
were found in human patients with IBD. When secreted
extracellularly, S100A12 contributes to innate immune re-
sponses and activates intracellular signalling cascades
leading to cytokine production and the induction of oxida-
tive stress in IBD patients [38]. In the present study,
S100A12 concentrations were higher in extracts from the
ileum than in other segments of the intestine. S100A12
detection in the intestinal mucosa may reflect the number
of neutrophils infiltrating the mucosa. Because of poor
agreement between pathologists evaluating the number of
duodenal neutrophils [37], we did not attempt to perform
neutrophil count comparisons between the different intes-
tinal sections. Therefore, we assume that the higher
S100A12 concentrations in the ileum may be due to the
high number of S100A12-expressing cells (neutrophils
and macrophages) within the ileal mucosa. Heilmann et
al. reported variations in the faecal concentrations of
S100A12 in healthy dogs [23]. An irregular distribution of
S100A12-expressing cells within the gastrointestinal mu-
cosa or variation in the concentration of faecal proteins
due to variations in the gastrointestinal passage were sug-
gested as possible reasons for this variation [23]. More-
over, Heilmann et al. reported a similar variation in other
faecal markers in healthy dogs [39, 40]. In our study, the
S100A12 concentration in all mucosal extracts ranged
from 2.5–237.6 μg/L. Similar variations in the S100A12
concentration were reported for normal duodenal and
cecal mucosal biopsies in humans [13]. In a study by
Leach et al., the S100A12 concentration ranged from 7–
36 μg/L in the culture supernatants of duodenal and cecal
mucosal biopsies obtained from 33 non-IBD control chil-
dren [13]. Duodenal and cecal biopsies were also cultured
and supernatants were collected for the determination of
S100A12 using the ELISA method. A similar variation
was also found in the concentration of calprotectin, an-
other member of the S100/calgranulin protein family, ran-
ging from 16–511 μg/L in the culture supernatants of
duodenal and cecal mucosal biopsies [13].
MPO is an enzyme found predominantly in neutro-
phils and in lower concentrations in monocytes and
macrophages. The quantification of MPO is well estab-
lished for the evaluation of intestinal inflammation in
humans and animal models of IBD [32, 33, 41–43]. The
number of neutrophils and consequently MPO enzyme
activity increase in inflammatory conditions such as hu-
man and animal models of IBD [29, 32, 33, 41–43]. Pre-
viously, MPO-derived hypochlorous acid (HOCl) was
shown to affect oxidative tissue damage in human IBD
[34]. In our study, MPO activities were higher in the
ileal, jejunal and duodenal mucosa than in the colonic
mucosa of healthy dogs. Moreover, its concentration was
higher in the jejunum than in the duodenum. The detec-
tion of MPO in the intestinal mucosa could reflect the
number of granulocytes infiltrating the mucosa. Varia-
tions in the MPO activity in our study in different parts
of the intestine in healthy dogs could be explained by
the disparity in the distribution of MPO-releasing cells,
such as the neutrophils and macrophages. Several stud-
ies investigated the distribution of immune cells in the
intestines of healthy dogs and cats [43–47]. However,
the results did not allow for conclusions concerning the
distribution of MPO, since the distribution of neutro-
phils as the primary source of MPO was not studied.
Macrophages, as a possible source of MPO, were de-
tected using the antibody MAC387 in two studies of the
intestines of normal cats [47] and dogs [43]. The authors
concluded that the number of MAC387 positive cells
was higher in the ileum than in other segments of the
intestine. However, to our knowledge, no study address-
ing the distribution of the MPO enzyme in different
parts of the normal intestinal mucosa of dogs or any
other species exists.
Considering the lack of sufficiently sensitive and specific
biomarkers for canine IBD, identifying such a marker
would substantially improve diagnosis and disease moni-
toring, and may potentially lead to a significant improve-
ment in patient care and quality of life. Faecal and serum
calprotectin, as a non-invasive biomarker, was found to in-
crease in dogs with IBD [48, 49]. In another study, faecal
concentrations of calprotectin were significantly higher in
dogs with chronic diarrhoea than in healthy control dogs
[50]. Furthermore, faecal S100A12 concentrations were
higher in dogs with IBD [25]. Whilst using non-invasive
Hanifeh et al. BMC Veterinary Research  (2015) 11:234 Page 4 of 8
biomarkers is more appropriate in determining the pres-
ence of gut inflammation, it is impossible to correlate fae-
cal S100A12 with certain histological subtypes of IBD
(lymophocytic-plasmacytic enteritis, eosinophilic enteritis,
etc.), since the specific type causing an increase and to
what degree remain unknown. In addition, measuring the
faecal S100A12 concentration does not allow for the as-
sessment of the specific part of the intestine from which
the S100A12 sample originates. In our opinion, knowing
which part of the intestine has the highest level of
S100A12 is important as a possible means for differentiat-
ing canine IBD subtypes. Faecal S100A12 may be valuable
for screening dogs suspected of having IBD and for moni-
toring disease activity, thus reducing the need for endos-
copy during disease follow-up. Increases in faecal
S100A12 are, therefore, viewed as indicative of endoscopy,
rather than being used as an alternative to endoscopy for
diagnosis [10]. In our study, we validated laboratory
methods to determine the biomarkers in tissues from their
proposed origin. Both mucosal S100A12 and MPO may
be valuable markers complementing invasive diagnostic
measures when used in combination with intestinal muco-
sal histology. This is an important basis for the study of
the role of such markers in different types of canine IBD.
To our knowledge, studies determining S100A12 and
MPO in intestinal mucosal samples from dogs suffering
from IBD remain unreported.
Extensive descriptions exist of the presence of in-
creased levels of both S100A12 and MPO in IBD pa-
tients in humans [10–16, 32, 33, 51, 52]. Ileal and
colonic mucosal S100A12 concentrations distinguished
active IBD human subjects from healthy controls with a
high sensitivity and specificity [15]. In another study,
S100A12 concentrations in duodenal and cecal mucosal
samples were significantly higher in children with IBD
compared with non-IBD controls [13]. Foell et al. found
a significant correlation between ileal and colonic muco-
sal S100A12 concentrations and intestinal tissue inflam-
mation [15]. In addition, a significant correlation was
also found between faecal and serum S100A12 concen-
trations and disease activity index in adults [11, 16] with
CD and UC. Therefore, some researchers concluded that
S100A12 is a suitable non-invasive marker for monitor-
ing disease activity [11, 16] and predicting disease re-
lapse both in CD and UC [16].
Studies of the correlation between S100A12 and the
paediatric Crohn’s disease activity index (PCDAI) in chil-
dren presented conflicting results. Whilst most studies re-
port no correlation [13, 14, 16], De Jong et al. found a
significant correlation in children with Crohn’s disease
[10]. Heilmann et al. reported similar findings in dogs with
IBD, finding a significant correlation between faecal
S100A12 and the canine chronic enteropathy clinical ac-
tivity index (CCECAI) [25]. Such studies need, however,
to take into consideration that both PCDAI and CCECAI
include a number of subjective elements, and conse-
quently do not always represent the actual inflammatory
burden, possibly leading to disagreements between results
from different studies.
Faecal myeloperoxidase levels were also significantly
correlated with histological indices of disease activity in
UC [51]. In addition, Wagner et al. showed that normal-
ised faecal MPO levels could be used to predict a
complete clinical response to treatment among patients
with CD or UC [52].
Whether S100A12 and MPO are also involved in the
pathogenesis of canine IBD remains unknown and re-
quires further investigation. In the current study, we
aimed to provide basic data for the determination of
S100A12 concentrations and MPO activities in the intes-
tinal mucosa of healthy dogs. Our study forms the basis
for on-going clinical trials comparing S100A12 and
MPO in subtypes of IBD. In future studies, immunohis-
tochemistry should also be included to assess the local-
isation of S100A12 and MPO in canine intestinal
mucosa and their association with intestinal pathologies
in dogs.
Conclusions
In conclusion, we determined the concentrations of
S100A12 and MPO in intestinal mucosa samples from
healthy dogs in this study, laying the groundwork for fu-
ture studies in canine chronic intestinal diseases, including
IBD. Both mucosal biomarkers may play a role in the ini-
tial detection of gut inflammation leading to further inves-
tigations confirming IBD or to differentiating between
IBD subtypes. Understanding the role of S100A12 and
MPO in the pathogenesis of chronic intestinal inflamma-
tion in future and evaluating their use as biomarkers to
distinguish between dogs with idiopathic IBD versus
healthy dogs or dogs with food-responsive diarrhoea,
antimicrobial-responsive diarrhoea and other gastrointes-
tinal diseases may provide the possibility of improving our
understanding of canine chronic intestinal inflammation
and the current treatment approach.
Methods
Sample collection and processing
We obtained intestinal tissue samples from 12 healthy la-
boratory Beagle dogs (8 males, 4 females; median age:
11 years, range: 10–13 years) during post-mortem exami-
nations upon completion of another unrelated study,
which was approved by the Finnish National Animal
Experiment Board (study license No. ESLH-2007-09833/
Ym-23). The dogs were housed according to the European
Union guidelines in groups in indoor pens with access to
outdoor runs. The indoor environmental temperature was
maintained at between 15–24 °C. The dogs were exposed
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to both natural and artificial light (from 7:00–16:00). They
were fed a standard commercial diet and were evaluated
as healthy based on history, physical examination, complete
blood count, serum biochemistry and faecal examination.
Immediately after humane euthanasia, their intestinal tracts
were opened longitudinally and flushed with cold sa-
line. Full-thickness tissue samples were collected from
four different segments of the intestine (duodenum,
jejunum, ileum and colon), snap-frozen in liquid ni-
trogen and stored at −80 °C for S100A12 and MPO
determination. For histological evaluation, parts of the
frozen intestinal tissue samples were later slowly
thawed and fixed in 4 % formaldehyde solution in
phosphate buffered saline (PBS) at 8 °C under per-
manent automatic rotation of the sample tube. Then,
the samples were trimmed and embedded in paraffin
wax. Sections (3–5 μm) were prepared and stained with
haematoxylin and eosin for histological examination.
Assessment of intestinal health
All dogs were healthy without any signs of gastrointes-
tinal diseases based on their histories, physical examina-
tions and laboratory examinations of their faeces and
blood. Histological assessment of the intestinal samples
was performed using the guidelines of the World Small
Animal Veterinary Association (WSAVA) Gastrointes-
tinal Standardisation Group [53]. In all small bowel sam-
ples, five morphological features (villous stunting,
epithelial injury, crypt distension, lacteal dilation and
mucosal fibrosis) and three types of infiltrated leukocytes
(intraepithelial lymphocytes, lamina propria lymphocytes
and lamina propria neutrophils) were selected and
scored from 0 to 3 according to the WSAVA standard-
isation guidelines. In the colonic samples, we also evalu-
ated the crypt hyperplasia, dilatation and distortion. The
total score was classified as normal (score 0–4), mild
(score 5–9), moderate (score 10–14), severe (score 15–19)
or very severe (score ≥ 20).
Measurement of mucosal S100A12 concentration
Snap-frozen intestinal mucosal samples (50 mg) from
the duodenum, jejunum, ileum and colon were homoge-
nised for 2 × 50 s at 5000 × g in 1 mL of ice-cold extrac-
tion buffer containing 50 mM Tris/HCl base, 150 mM
NaCl, 10 mM CaCl2, 0.2 mM NaN3 and 0.01 % (v/v)
Triton X-100 (pH 7.6) in the presence of EDTA-free
protease inhibitor cocktail tablets (Complete EDTA-free
tablets, Roche, Basel, Switzerland) using Precellys 24 cer-
amic beads at 4 °C (Bertin technologies, Paris, France).
After homogenisation, samples were centrifuged at 13
000 × g and 4 °C for 10 min, and the supernatants were
collected and stored at −80 °C for the measurement of
S100A12. The S100A12 concentration was determined
in intestinal mucosal samples obtained from four
different intestinal segments from 12 healthy laboratory
Beagle dogs using the ELISA method, which was re-
cently developed and validated [25]. Briefly, immuno-
assay plates were coated with affinity-purified polyclonal
anti-cA12Ab and were blocked with Tris-buffered saline
(TBS)-Tween-10 % BSA. Plates were then incubated
with duplicates of standard cA12 solutions, assay con-
trols or mucosal extracts diluted in TBS-Tween-3 %
BSA, after which they were incubated with horseradish
peroxidase-labelled anti-cA12 polyclonal Ab. A 3,3’,5,5’-
tetramethylbenzidine substrate was used for colour de-
velopment and absorbance at 450 nm was measured.
S100A12 concentrations in extracts of snap-frozen intes-
tinal mucosal tissues were measured using the same lot
of reagents for all samples and were reported as μg/L of
the intestinal mucosal supernatant.
Measurement of mucosal MPO activity
For MPO measurement, snap-frozen mucosal samples
from the duodenum, jejunum, ileum and colon were
weighed, suspended in 1 ml of ice-cold extraction buffer
per 50 mg of tissue and homogenised for 2 × 50 s at
5000 × g using Precellys 24 ceramic beads at 4 °C (Bertin
technologies, France). The extraction buffer contained
hexadecyltrimethylammonium bromide (HTAB; 0.5 %
weight/volume [w/v]) in a 50-mM sodium phosphate
buffer (pH 5.4). After homogenisation, samples were
centrifuged at 4000 × g and 4 °C for 20 min, and the su-
pernatants were collected and stored at −80 °C. MPO
activity was determined in intestinal mucosa using the
method described by Marquez and Dunford [54] with
some modifications. The final assay buffer was supple-
mented with HTAB as a cationic detergent. Briefly, the
reaction mixture consisted of 170 μL of sodium phos-
phate buffer (80 mM, pH 5.4) with HTAB (0.5 % w/v)
and 3,3’,5,5’-tetramethylbenzidine (1.6 mmol/L). Five μL
of supernatant and 5 μL of distilled water were added to
this reaction mixture, and the mixture was incubated
while shaking at 37 °C for 6 min, then adding 20 μL of
H2O2 (0.3 mmol/L). The final concentrations of the re-
action mixture are reported in parentheses. After the
addition of H2O2, kinetic measurement for 60 s was ini-
tiated at a wavelength of 620 nm using an automatic
chemical analyser (Kone Pro, ThermoFisher Scientific,
Vantaa, Finland). MPO activity was expressed as delta
absorbance units per minute (ΔA/min).
The colorimetric method for MPO determination was
validated for precision, accuracy and recovery. Intra- and
inter-assay precisions were determined as coefficients of
variation calculated from six different small and large in-
testinal mucosa samples within an analytical run (n = 10)
and across different runs (n = 10). The linearity was evalu-
ated using serial dilutions of the same mucosal samples
(1:2, 1:4, 1:8 and 1:16) by calculating the mean and
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standard deviation (SD) of the observed and expected ra-
tios (%). The spiking recovery was analysed among six dif-
ferent spiking activity samples of human MPO-pure
enzyme (0.066, 0.109, 0.161, 0.191, 0.318 and 0.477 ΔA/
min) in five different small and large intestinal mucosa
samples. The mean and SD values were calculated for the
observed and expected ratios (%).
Statistical analysis
Data are presented as medians (interquartile range). The
differences in the S100A12 concentrations and MPO
activities between the four different segments of the in-
testine (duodenum, jejunum, ileum and colon) were ana-
lysed using an analysis of variance (ANOVA) model. To
satisfy the assumptions of normality and the homogen-
eity of variances, the original values were transformed to
a logarithmic scale. If the results of the Levene’s test
were significant (p < 0.05) following data transformation,
we used an ANOVA-Welch test for further analysis. The
fitted model included the section of intestine as the fixed
effect and the dog as the random effect. Tukey’s HSD
test was used in pairwise comparisons to control for
multiple comparisons, and we used the Tamhane’s T2
test for variables with significant differences in the vari-
ance. For all analyses, we considered values of p < 0.05
as significant. All statistical analyses were performed
using the SAS 9.3 statistical software program (SAS In-
stitute Inc., Cary, NC, USA).
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